BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor i receptor (IGF-IR) gene expression in USC cell lines

International Journal of Gynecological Cancer

Volumn 22, Issue 5, 2012, Pages 748-754

  Amichay, Keren ^a   Kidron, Debora ^a   Attias Geva, Zohar ^b   Schayek, Hagit ^b   Sarfstein, Rive ^b   Fishman, Ami ^a   Werner, Haim ^b   Bruchim, Ilan ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

BRCA1; IGF I receptor; Insulin like growth factor I (IGF I); Uterine serous carcinoma

Indexed keywords

BRCA1 PROTEIN; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TISSUE SECTION; UTERUS CARCINOMA; UTERUS SEROUS CARCINOMA; WESTERN BLOTTING;

BLOTTING, WESTERN; BRCA1 PROTEIN; CARCINOMA, PAPILLARY; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; NEOPLASM METASTASIS; PHOSPHORYLATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84863667602     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318254011f     Document Type: Article

References (25)

1. Baserga R, Hongo A, Rubini M, et al. The IGF-IR receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997;1332:105-126.
2. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995;16:143Y163.
3. Valentinis B, Baserga R. IGF-1 receptor signaling in transformation and differentiation. Mol Pathol. 2001; 54:133-137. (Pubitemid 32539602)
4. Baserga R, Morrione A. Differentiation and malignant transformation: two roads diverged in a wood. J Cell Biochem. 1999;32-33:68-75. (Pubitemid 30041812)
5. Ouban A, Muraca P, Yeatman T, et al. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 2003;34:803-808. (Pubitemid 37040618)
6. Ayabe T, Tsutsumi O, Sakai H, et al. Increased circulating levels of IGF-I and decreased circulating levels of IGFBP1 in postmenopausal women with endometrial cancer. Endocr J. 1997;4:419-424. (Pubitemid 27310429)
7. McCampbell AS, Broaddus RR, Loose DS, et al. Overexpression of the insulin-like growth factor-I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006;2:6363-6378.
8. Hirano S, Ito N, Takahashi S, et al. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol. 2004;25:187-191. (Pubitemid 38268694)
9. Abramovitch S, Glaser T, Ouchi T, et al. BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett. 2003;541:149-154. (Pubitemid 36428934)
10. Maor SB, Abramovitch S, Erdos MR, et al. BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab. 2000;69:130-136. (Pubitemid 30180697)
11. Maor S, Yosepovich A, Papa MZ, et al. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett. 2007;257: 236-243. (Pubitemid 47538827)
12. Bruchim I, Amichay K, Kidron D, et al. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer. 2010;20:1148-1153.
13. Hendrickson A Martinez J Ross R, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
14. Gallion JR, Nagell DF, Powell ES, et al. Stage I serous papillary carcinoma of the endometrium. Cancer. 1989;63:2224-2228.
15. Fan S, Wang J-A, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999;284: 1354-1356. (Pubitemid 29289660)
16. Werner H, Rauscher FJ III, Sukhatme VP, et al. Transcriptional repression of the insulin-like growth factor I receptor (IGF-IR) gene by the tumor suppressorWT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem. 1994;269: 12577-12582.
17. Abramovitch S, Werner H. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene. Horm Metab Res. 2003;35:758-762. (Pubitemid 38058180)
18. Gotlieb WH, Bruchim I, Gu J, et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol. 2006;100:389-396. (Pubitemid 43075275)
19. Lavie O, Hornreich G, Ben Arie A, et al. BRCA germline mutation in Jewish woman with uterine serous papillary carcinoma. Gynecol Oncol. 2004;92:521-524. (Pubitemid 38183139)
20. Goshen R, Chu W, Elit L, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 2000;79:477-481.
21. Maor S, Papa MZ, Yarden RI, et al. Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm Metab Res. 2007;39:179-185. (Pubitemid 46580615)
22. Schayek H, Haugk K, Sun S, et al. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor-I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res. 2009;15: 1558-1565.
23. Hudelist G, Wagner T, Rosner M, et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer. 2007;14:1053-1062. (Pubitemid 351252436)
24. Neuhausen SL, Brummel S, Ding YC, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 2009;11:R76.
25. Bruchim I, Attias Z,Werner H. Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets. 2009;13:1-15.